| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
29,500,000 |
| Market
Cap: |
20.95(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.6979 - $1.66 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Quince Therapeutics is a clinical stage biopharmaceutical company focused on therapeutic approaches to improve the lives of patients diagnosed with Alzheimer's and degenerative diseases. Co.'s portfolio of gingipain inhibitors are orally administered, brain-penetrating small molecules. Co.'s pipeline includes proprietary drug candidates for the treatment of CNS disorders including Alzheimer's disease, for the treatment of oncology applications including the prevention of oral squamous cell carcinoma, and for the treatment of conditions like periodontitis. Co.'s pipeline also includes proprietary irreversible protease inhibitors under development for the treatment of coronavirus infection.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
748,198 |
748,198 |
| Total Buy Value |
$0 |
$0 |
$909,016 |
$909,016 |
| Total People Bought |
0 |
0 |
4 |
4 |
| Total Buy Transactions |
0 |
0 |
19 |
19 |
| Total Shares Sold |
0 |
0 |
0 |
1,871 |
| Total Sell Value |
$0 |
$0 |
$0 |
$1,834 |
| Total People Sold |
0 |
0 |
0 |
1 |
| Total Sell Transactions |
0 |
0 |
0 |
1 |
| End Date |
2024-03-17 |
2023-12-15 |
2023-06-16 |
2022-06-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Monohon Ted |
Chief Accounting Officer & VP |
• – – |
2022-12-05 |
4 |
D |
$0.72 |
$1,181 |
D/D |
(1,640) |
29,311 |
|
- |
|
| Monohon Ted |
Chief Accounting Officer & VP |
• – – |
2022-09-06 |
4 |
D |
$1.64 |
$2,493 |
D/D |
(1,520) |
30,951 |
|
- |
|
| Mcdowell Caryn Gordon |
Chief Legal & Adm. Officer |
• – – |
2022-06-06 |
4 |
AS |
$2.86 |
$30,923 |
D/D |
(10,800) |
122,500 |
|
-63% |
|
| Mcdowell Caryn Gordon |
Chief Legal & Adm. Officer |
• – – |
2022-06-06 |
4 |
D |
$2.86 |
$19,183 |
D/D |
(6,700) |
133,300 |
|
- |
|
| Monohon Ted |
Chief Accounting Officer & VP |
• – – |
2022-06-06 |
4 |
D |
$3.12 |
$4,770 |
D/D |
(1,529) |
32,471 |
|
- |
|
| Holsinger Leslie |
EVP, Preclinical Development |
• – – |
2022-06-06 |
4 |
D |
$2.86 |
$31,231 |
D/D |
(10,920) |
148,080 |
|
- |
|
| Smith Karen L. |
Chief Medical Officer |
• – – |
2022-05-19 |
4/A |
A |
$0.00 |
$0 |
D/D |
170,354 |
194,690 |
|
- |
|
| Hannah Brendan |
Chief Business Officer |
• – – |
2022-05-19 |
4/A |
A |
$0.00 |
$0 |
D/D |
113,569 |
129,793 |
|
- |
|
| Thye Dirk |
Chief Executive Officer |
• • – |
2022-05-19 |
4/A |
A |
$0.00 |
$0 |
D/D |
216,322 |
280,911 |
|
- |
|
| Low Philip S |
Director |
– • – |
2022-05-19 |
4 |
A |
$0.00 |
$0 |
I/I |
63,974 |
63,974 |
|
- |
|
| Low Philip S |
Director |
– • – |
2022-05-19 |
4 |
A |
$0.00 |
$0 |
D/D |
455,309 |
455,309 |
|
- |
|
| Lamond David |
Director |
– • – |
2022-05-19 |
4 |
A |
$0.00 |
$0 |
I/I |
200,002 |
1,734,722 |
|
- |
|
| Thye Dirk |
Chief Executive Officer |
• • – |
2022-05-19 |
4 |
A |
$0.00 |
$0 |
D/D |
64,589 |
64,589 |
|
- |
|
| Hannah Brendan |
Chief Business Officer |
• – – |
2022-05-19 |
4 |
A |
$0.00 |
$0 |
D/D |
16,224 |
16,224 |
|
- |
|
| Smith Karen L. |
Chief Medical Officer |
• – – |
2022-05-19 |
4 |
A |
$0.00 |
$0 |
D/D |
24,336 |
24,336 |
|
- |
|
| Monohon Ted |
Chief Accounting Officer & VP |
• – – |
2022-03-03 |
4 |
A |
$0.00 |
$0 |
D/D |
34,000 |
34,000 |
|
- |
|
| Mcdowell Caryn Gordon |
Chief Legal & Adm. Officer |
• – – |
2022-03-03 |
4 |
A |
$0.00 |
$0 |
D/D |
140,000 |
140,000 |
|
- |
|
| Holsinger Leslie |
EVP, Preclinical Development |
• – – |
2022-03-03 |
4 |
A |
$0.00 |
$0 |
D/D |
155,500 |
159,000 |
|
- |
|
| Lowe Christopher P. |
Interim CEO, COO & CFO |
• – – |
2022-03-03 |
4 |
A |
$0.00 |
$0 |
D/D |
175,000 |
265,000 |
|
- |
|
| Detke Michael J. |
Chief Medical Officer |
• – – |
2022-03-03 |
4 |
A |
$0.00 |
$0 |
D/D |
140,000 |
140,000 |
|
- |
|
| Lynch Casey |
Chief Executive Officer |
• • – |
2021-11-18 |
4 |
OE |
$0.46 |
$27,600 |
D/D |
60,000 |
109,895 |
|
- |
|
| Dominy Stephen S. |
Chief Scientific Officer |
• • – |
2021-11-12 |
4 |
B |
$14.40 |
$10,987 |
I/I |
763 |
1,217,086 |
2.58 |
-58% |
|
| Mcloughlin Margaret |
Director |
– • – |
2021-10-08 |
4 |
AS |
$88.93 |
$88,930 |
D/D |
(1,000) |
0 |
|
-95% |
|
| Mcloughlin Margaret |
Director |
– • – |
2021-10-08 |
4 |
OE |
$17.00 |
$17,000 |
D/D |
1,000 |
1,000 |
|
- |
|
| Lowe Christopher P. |
COO & Chief Financial Officer |
• – – |
2021-10-05 |
4 |
AS |
$98.50 |
$488,856 |
D/D |
(4,963) |
60,000 |
|
-95% |
|
113 Records found
|
|
Page 2 of 5 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.01 (1.73%) 
